Framingham Risk Score Prediction at 12 Months in the STANDFIRM Randomized Control Trial
Our findings suggest that change in FRS as an end point in secondary stroke trials may have limited value as it is largely determined at baseline. In this cohort, category boosting was the optimal method to predict future FRS but not change in FRS.
Authors
- Thanh G. Phan (ORCID: https://orcid.org/0000-0003-3400-6323)
- Amanda Gay Thrift (ORCID: https://orcid.org/0000-0001-8533-4170)
- Muideen Tunbosun Olaiya (ORCID: https://orcid.org/0000-0002-4070-0533)
- Chris Bladin (ORCID: https://orcid.org/0000-0002-1729-0855)
- Mark Raymond Nelson (ORCID: https://orcid.org/0000-0001-9941-7161)
- Velandai Srikanth (ORCID: https://orcid.org/0000-0002-8442-8981)
- Richard Gerraty (ORCID: https://orcid.org/0000-0002-7770-9953)
- Sharyn M. Fitzgerald (ORCID: https://orcid.org/0000-0003-1840-6079)
- Dominique Ann-Michele Cadilhac (ORCID: https://orcid.org/0000-0001-8162-682X)
- Joosup Kim
- Henry Ma
Institutions
- University of Tasmania (AU)
- Epworth Hospital (AU)
- Australian Regenerative Medicine Institute (AU)
- Monash Medical Centre (AU)
- Ambulance Victoria (AU)
- Menzies School of Health Research (AU)
- Peninsula Health (AU)
- Monash Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1161/jaha.124.040254
- Citations
- 2
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 6.26